Abstract Objective To explore the role of berberine (BBR) in ameliorating coronary endothelial cell injury in Kawasaki disease (KD) by regulating the complement and coagulation cascade. Methods Human coronary artery endothelial cells (HCAEC) were divided into a healthy control group, a KD group, and a BBR treatment group (n=3 for each group). The healthy control group and KD group were supplemented with 15% serum from healthy children and KD patients, respectively, while the BBR treatment group received 15% serum from KD patients followed by the addition of 20 mmol/L BBR. Differential protein expression was analyzed and identified using isobaric tags for relative and absolute quantitation technology and liquid chromatography-tandem mass spectrometry, followed by GO functional enrichment analysis and KEGG signaling pathway enrichment analysis of the differential proteins. Western blot was used to detect differential protein expression. Results A total of 518 differential proteins were identified between the KD group and the healthy control group (300 upregulated proteins and 218 downregulated proteins). A total of 422 differential proteins were identified between the BBR treatment group and the KD group (221 upregulated proteins and 201 downregulated proteins). Bioinformatics analysis showed that compared to the healthy control group, the differential proteins in the KD group were enriched in the complement and coagulation cascade and ribosome biogenesis in eukaryotes. Compared to the KD group, the differential proteins in the BBR treatment group were also enriched in the complement and coagulation cascade and ribosome biogenesis in eukaryotes. Western blot results indicated that compared to the healthy control group, the expression of complement C1q subcomponent subunit C (C1QC), kininogen-1 (KNG1), complement C1s subcomponent (C1S), and C4b-binding protein alpha chain (C4BPA) was increased in the KD group (P<0.05). Compared to the KD group, the expression of KNG1, C1S, C1QC, and C4BPA was decreased in the BBR treatment group (P<0.05). Conclusions The complement and coagulation cascade may be involved in the regulation of BBR treatment for coronary injury in KD, and C1QC, KNG1, C1S, and C4BPA may serve as biomarkers for this treatment.
LIAO Jin-Wen,GUO Xin,LIANG Bo et al. Berberine ameliorates coronary artery endothelial cell injury in Kawasaki disease through complement and coagulation cascades[J]. CJCP, 2025, 27(1): 101-108.
LIAO Jin-Wen,GUO Xin,LIANG Bo et al. Berberine ameliorates coronary artery endothelial cell injury in Kawasaki disease through complement and coagulation cascades[J]. CJCP, 2025, 27(1): 101-108.
Center for Diagnosis and Treatment of Kawasaki Disease/Children's Hospital of Shaanxi Provincial People's Hospital, National Children's Medical Center/Beijing Children's Hospital, Capital Medical University, Children's Hospital, Shanghai Jiao Tong University School of Medicine, National Regional Medical Center/Shengjing Hospital of China Medical University, National Clinical Key Specialty/Department of Intensive Care Medicine, Shanghai Children's Hospital, General Pediatric Group of Pediatrician Branch of Chinese Medical Doctor Association, Expert Committee of Advanced Training for Pediatrician, China Maternal and Children's Health Association, National Health Commission Key Laboratory for Tropical Disease Prevention and Control, Yan'an University Affiliated Hospital, Editorial Department of Chinese Journal of Contemporary Pediatrics. Evidence-based guidelines for the diagnosis and treatment of Kawasaki disease in children in China (2023)[J]. CJCP, 2023, 25(12): 1198-1210.
